We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
By Joe Hoppe
AstraZeneca PLC said Monday that its Imfinzi product has been recommended for marketing authorization in the European Union for treating adults with biliary tract cancer, in combination with chemotherapy.
The Anglo-Swedish pharma major said that the European Medicines Agency based its positive opinion on results from the Topaz-1 Phase 3 trial.
The studies showed that the combination of Imfinzi and chemotherapy reduced the risk of death by 24% when compared to chemotherapy alone. Around 23.6% of patients were still alive after two years, compared with 11.5% of patients given chemotherapy alone.
The treatment is for unresectable or metastatic biliary tract cancer, a group of rare and aggressive cancers. It was generally well-tolerated by patients.
Imfinzi plus chemotherapy is already approved in the U.S., Canada, South Korea and Brazil for biliary tract cancer, and regulatory applications are under review in Japan and several other countries.
"The combination of [Imfinzi] and chemotherapy is a significant advance for patients after more than a decade of limited progress, and this regimen should become a new standard of care option once approved," said Juan Valle, a lead investigator in the trial and professor of medical oncology at the University of Manchester.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
November 14, 2022 02:34 ET (07:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions